The firm's financial position is increasingly precarious, with total assets contracting from $5.0M in 2024Q2 to $2.5M in 2026Q1, while the accumulated deficit has reached -$106.2M.
| Total Current Assets | 2.42M | 2.85M | 2.67M | 1.85M | 6.84M | 3.96M | 3.25M | 8.91M | 4.53M | 22.17M | 197K | 14K |
| Cash & Short-Term Investments | 2.42M | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M | 3.13M | 8.74M | 2.67M | 21.78M | 197K | 14K |
| Cash Only | 2.42M | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M | 3.13M | 8.74M | 2.67M | 11.78M | 197K | 14K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 90K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 51.99 | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 78K | 0 | 0 | 0 | 0 | 0 | 1.7M | 0 | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 67K | 0 | 0 | 113K | 170K | 1.85M | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 67K | 0 | 0 | 113K | 170K | 1.85M | 0 | 0 | 0 |
| Total Assets | 2.47M | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M | 3.25M | 8.91M | 4.53M | 22.17M | 197K | 14K |
| Asset Turnover | 0.42x | 0.48x | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 3.69% | 9.69% | 44.43% | -72.97% | 72.85% | 22.03% | -63.6% | 97.02% | -79.59% | 11153.81% | 1307.14% | - |
| Total Current Liabilities | 1.27M | 1.1M | 816K | 1.2M | 3.58M | 509K | 886K | 2.12M | 5.16M | 2.79M | 6.42M | 2.45M |
| Accounts Payable | 0 | 0 | 155K | 401K | 150K | 304K | 172K | 354K | 3.09M | 1.54M | 334K | 491K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.85M | 1.17M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.75M | 0 |
| Other Current Liabilities | 1.27M | 1.1M | 34K | 784K | 2.61M | 24K | 0 | 1M | 0 | 0 | 1.66M | 114K |
| Current Ratio | 1.90x | 2.60x | 3.27x | 1.55x | 1.91x | 7.78x | 3.66x | 4.22x | 0.88x | 7.95x | 0.03x | 0.01x |
| Quick Ratio | 1.90x | 2.60x | 3.27x | 1.55x | 1.91x | 7.78x | 3.66x | 4.22x | 0.88x | 7.95x | 0.03x | 0.01x |
| Cash Conversion Cycle | 51.99 | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.03M | 2.7M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.03M | 2.7M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.27M | 1.1M | 816K | 1.2M | 3.58M | 509K | 886K | 2.12M | 5.16M | 2.79M | 8.45M | 5.15M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.87M | 3.87M |
| Net Debt | -2.42M | -2.85M | -2.59M | -1.78M | -6.71M | -3.76M | -3.13M | -8.74M | -2.67M | -11.78M | 5.68M | 3.85M |
| Debt / Equity | 0.00x | - | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - | 8.79x |
| Net Debt / EBITDA | 1.18x | - | - | - | - | - | - | - | - | - | - | 8.76x |
| Interest Coverage | - | - | - | - | -2.11x | - | - | - | - | -31.69x | -4.19x | -11.59x |
| Total Equity | 1.2M | 1.83M | 1.86M | 654K | 3.27M | 3.45M | 2.36M | 6.8M | -631K | 19.38M | -8.25M | -5.13M |
| Equity Growth % | -36.51% | -1.29% | 183.79% | -79.98% | -5.36% | 46.29% | -65.31% | 1177.65% | -103.26% | 334.97% | -60.62% | - |
| Book Value per Share | 0.36 | 0.59 | 0.14 | 4.63 | 112.10 | 3.05 | 2.14 | 6.49 | -0.92 | 43.81 | -13.99 | -9.23 |
| Total Shareholders' Equity | 1.2M | 1.83M | 2.8M | 1.58M | 3.9M | 3.45M | 2.36M | 6.8M | -631K | 19.38M | -8.25M | -5.13M |
| Common Stock | 0 | 0 | 0 | 3K | 0 | 0 | 2K | 2K | 1K | 1K | 1K | 1K |
| Retained Earnings | -106.18M | -105.49M | -102.58M | -90.93M | -80.55M | -77M | -73.27M | -68.12M | -42.21M | -20.66M | -8.4M | -5.23M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.1M | 49K | 40K |
| Minority Interest | 0 | 0 | -941K | -928K | -639K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent Capital Depletion Risk
According to recent SEC filings, ATXI's total assets have declined from $5.0M in 2024Q2 to $2.5M by 2026Q1, reflecting a consistent contraction in the company's resource base as it continues to fund clinical development without a sustainable, recurring revenue stream to replenish its capital reserves.
The steady decline in total assets suggests that the company is consuming its limited capital to sustain operations rather than building value through commercial growth. This trajectory implies that the firm's survival is increasingly dependent on external financing rather than internal value creation.
As reported in quarterly financial statements, the company's cash position has dwindled to $2.4M as of 2026Q1, a significant reduction from the $4.9M peak observed in 2024Q2, which highlights the precarious nature of the firm's liquidity buffer in the face of ongoing, non-discretionary R&D expenditures.
The current ratio of 1.90, while appearing superficially adequate, masks the reality that the company lacks the operational cash flow to support its burn rate. Investors should monitor the rapid depletion of cash, as it suggests that the company may be forced to seek dilutive capital infusions in the near term.
Based on the company's reported figures, the retained earnings balance has plummeted to -$106.2M as of 2026Q1, illustrating the profound and persistent destruction of shareholder equity resulting from years of unsuccessful regulatory outcomes and high-cost clinical trial requirements for its lead analgesic candidate.
The persistent negative retained earnings indicate that the company has failed to achieve a return on invested capital, effectively eroding the equity base over time. This trend suggests that the firm's capital structure is heavily reliant on continuous equity issuance, which may further dilute existing shareholders.
As disclosed in the balance sheet data, the company reports zero property, plant, and equipment (PPE) and zero goodwill, which suggests that the firm's entire valuation is tethered to intangible intellectual property that has yet to receive the necessary regulatory validation for commercialization.
The absence of tangible assets underscores the high-risk nature of the business model, as there is no physical collateral to support the company's valuation in the event of further regulatory setbacks. This lack of asset diversity implies that the firm's balance sheet is essentially a binary bet on the success of its clinical pipeline.
Quick answers to the most common questions about buying ATXI stock.
As of 2025, Avenue Therapeutics, Inc. (ATXI) had total assets of $2.9M including $2.9M in current assets.
Avenue Therapeutics, Inc. (ATXI) carries total debt of $0.0M, offset by $2.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Avenue Therapeutics, Inc. (ATXI) has total shareholders' equity (book value) of $1.8M ($0.59 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Avenue Therapeutics, Inc. (ATXI) reported a current ratio of 2.60x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.